Aug 01, 2019 / 12:00PM GMT
Operator
Good morning and welcome to the second quarter of 2019 Adaptimmune earnings conference call. My name is Carla, and I will be your conference operator today. (Operator Instructions)
And now I would like to turn the call over to Juli Miller. Go ahead, please.
Juli P. Miller - Adaptimmune Therapeutics plc - Director of IR
Good morning, and welcome to Adaptimmune's conference call to discuss our second quarter 2019 financial results and other business update. We issued 2 press releases earlier this morning, and I would ask you to please review the full text of our forward-looking statements there. As a brief reminder, we anticipate making projections during this call and actual results could differ materially due to a number of factors, including those outlined in our latest filings with the SEC.
James Noble, our Chief Executive Officer; Adrian Rawcliffe, incoming Adaptimmune's CEO; and Rafael Amado, our President of Research and Development are with me for the prepared portion of this call. Bill Bertrand, our Chief Operating Officer; Helen Tayton
Q2 2019 Adaptimmune Therapeutics PLC Earnings Call Transcript
Aug 01, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers